Nonmetastatic Castration-resistant Prostate Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

FDA approval · 2025-06-03
FDA Approved: NUBEQA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved Bayer's supplemental application for NUBEQA (darolutamide), expanding or updating its labeling related to nonmetastatic castrat…
FDA approval · 2023-10-13
FDA Approved: NUBEQA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for NUBEQA (darolutamide) submitted by Bayer HealthCare Pharmaceuticals Inc.
FDA approval · 2021-01-07
FDA Approved: NUBEQA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for NUBEQA (darolutamide) filed by Bayer, updating the labeling for its use in nonmetastatic cas…
CLINICAL_TRIALS trial_result · 2018-07-12
Clinical Trial Update: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer [Phase 3]
Phase 3 clinical trial update for enzalutamide in nonmetastatic castration-resistant prostate cancer; the study is completed and results wer…
CLINICAL_TRIALS trial_result · 2016-04-04
Clinical Trial Update: Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen [Phase 2]
Phase 2 trial evaluating TAK-700 for safety and efficacy in nonmetastatic castration-resistant prostate cancer with rising PSA has completed…
Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.